• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Methylphenidate associated with short-term reduction in symptoms of apathy in patients with Alzheimer disease

byYuchen DaiandMichael Pratte
September 28, 2021
in Chronic Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Methylphenidate provides a treatment approach with modest but potentially clinically significant benefit for apathy symptoms in patients with Alzheimer disease.

2. The efficacy of methylphenidate had a relatively short onset, and its effect was sustainable for at least 6 months.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Apathy is one of the most common distinguishing symptoms in individuals with Alzheimer disease (AD) characterized by executive cognitive dysfunction leading patients to suffer from decreased daily function and specific cognitive deficits over time. This gradual deterioration in executive function is associated with significant caregiver burden, excess disability, increased medical costs, and mortality. This placebo-controlled randomized clinical trial, the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2), sought to determine the clinical efficacy of methylphenidate compared to placebo for reducing the severity of apathy in patients with AD. The primary endpoints of the analysis included 1) change from baseline to 6 months in the Neuropsychiatric Inventory (NPI) apathy subscale or 2) improved rating on the Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change. Secondary endpoints included safety profile, change in cognition, and quality of life. Among 200 patients with AD, methylphenidate therapy vs placebo was safe and associated with a decrease in apathy symptoms and severity as measured via the NPI within 2 months and sustained for 6 months. These findings suggested that methylphenidate provides a treatment approach with modest but potentially clinically significant benefit for patients with AD and caregivers. The efficacy of methylphenidate had a relatively short onset, and its effect was sustainable for at least 6 months. A limitation of this study was that the majority of participants were White individuals from US and Canadian academic medical centers that may not generalize to other populations or non-AD forms of dementia

Click to read the study in JAMA Neurology

Click to read an accompanying editorial in JAMA Neurology

Relevant Reading: Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge

RELATED REPORTS

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Rare APOE missense variants V236E and R251G associated with substantial reduction in risk of Alzheimer disease

In-Depth [randomized controlled trial]: This multicenter, phase 3 randomized clinical trial included 200 patients with AD, mild to moderate cognitive impairment, and frequent and/or severe apathy randomized 1:1 to receive 10 mg of methylphenidate (n = 99) vs matching placebo (n = 101) (median age [IQR], 76 [71-81] years; 68 [34%] female). The trial was conducted between August 2016 and July 2020 from 1 Canadian and 9 US centers. Overall, methylphenidate therapy resulted in a larger decrease in the NPI apathy score from baseline to 6 months compared to placebo (mean difference, -1.25; 95%CI, -2.03 to -0.47; P = .002). The most significant decrease in NPI apathy score was observed in the initial 100 days, with a significant hazard ratio for the proportion of participants without apathy symptoms receiving methylphenidate compared to placebo (HR, 2.16; 95%CI, 1.19-3.91; P = .01). Using the Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change, the odds ratio of an improvement in ratings at 6 months for methylphenidate therapy was 1.90 (95%CI, 0.95-3.84; P = .07). Using a longitudinal model, the difference in mean change from baseline to 6 months estimated was 1.43 (95%CI, 1.00-2.04; P = .048). There were no significant differences in the safety profile among treatment groups.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: alzheimerAlzheimer’s diseasecognitive impairment
Previous Post

United States providers increased prescribing of buprenorphine/naloxone

Next Post

Carotid artery stenting and carotid endarterectomy show similar efficacy for stroke prevention in high-risk carotid artery stenosis

RelatedReports

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial
StudyGraphics

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 21, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 17, 2022
Amyloid pathology may be detected decades prior to Alzheimer’s diagnosis
Chronic Disease

Rare APOE missense variants V236E and R251G associated with substantial reduction in risk of Alzheimer disease

June 2, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms

May 26, 2022
Next Post
2 Minute Medicine Rewind October 12 – 19, 2014

Carotid artery stenting and carotid endarterectomy show similar efficacy for stroke prevention in high-risk carotid artery stenosis

The Important Things You Learn When You Move to a Foreign Country

#VisualAbstract: Probiotics not effective at reducing incidence of ventilator-associated pneumonia in critically ill patients

#VisualAbstract: Probiotics not effective at reducing incidence of ventilator-associated pneumonia in critically ill patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.